Shanghai Securities News China Securities Network News (reporter Confucius Ziyuan) Frontier Biology issued an announcement of stock trading changes. The company's research product FB2001 is an injectable new crown pneumonia virus protease inhibitor, the target is the new crown pneumonia virus 3CL main protease, as of the disclosure date of this announcement, the world's same target new drug has been Pfizer's oral new crown drug (Paxlovid) has been authorized for emergency use by the US Food and Drug Administration (FDA) for the treatment of mild to moderate new crown pneumonia patients with poor prognosis risk, non-hospitalization, the company's product FB2001 is an injectable protease inhibitor, It is intended to be used to treat hospitalized patients with moderate and severe COVID-19; currently approved drugs for the treatment of hospitalized patients with COVID-19 include Remdesivir of Gilead Corporation. Investors are kindly requested to make rational decisions and invest prudently.
![Musk: My family and I have been vaccinated against mandatory vaccinations[fig]](data:image/gif;base64,R0lGODlhAQABAIAAAP///wAAACwAAAAAAQABAAACAkQBADs=)